Table 2:
Characteristics of biopsy outcomes and prostate cancer cases stratified by race
| Black | Non-Black | ||
| (N =287) | (N =277) |
p value1 |
|
| N (%) | N (%) | ||
| Biopsy Outcomes | |||
| Cancer on Biopsy | 181 (63.1) | 115 (41.5) | <0.001 |
| ≥ Gleason 3+4 | 86 (47.5) | 46 (40.0) | <0.001 |
| ≥ Gleason 4+4 | 26 (14.4) | 11 (9.6) | 0.02 |
| Black cancer cases | Non-Black cancer cases |
p value2 |
|
| (N =181) | (N =115) | - | |
| N (%) | N (%) | - | |
|
Clinical TNM Stage | |||
| T1c (N0/x, M0/x) | 107 (59.1) | 74 (64.3) | 0.01 |
| T2a (N0/x, M0/x) | 26 (14.4) | 18 (15.6) | |
| T2b/c (N0/x, M0/x) | 29 (16.0) | 16 (13.9) | |
| T3a (N0/x, M0/x) | 2 (1.1) | 1 (0.9) | |
| T3b (N0/x, M0/x) | 1 (0.6) | 1 (0.9) | |
| T4 (N0/x, M0/x) | 1 (0.6) | 0 (0) | |
| N1 | 6 (3.3) | 2 (1.7) | |
| M1 | 14 (7.7) | 4 (3.5) | |
| NCCN Risk Strata | |||
| Very Low/Low | 67 (37.0) | 48 (41.7) | 0.047 |
| Intermediate | 56 (30.9) | 45 (39.1) | |
| High/Very High/Metastatic |
58 (32.0) | 22 (19.1) | |
|
Prostate Biopsy Cores |
Median (IQR) | Median (IQR) | |
| Positive Cores | 4.5 (2–8) | 3 (2–6) | 0.01 |
| % Positive Cores | 41.7 (16.7–66.7) | 25.0(16.7 −50.0) | 0.01 |
Note: TNM = Tumor, Node, Metastasis Staging System; NCCN = 2016 National Comprehensive Cancer Network prostate cancer Guidelines;
1
Using χ2 test;
2
Using Mann-Whitney U-test;
3
bold type indicates p <0.05